BioMarin (BMRN) legal chief receives options, RSUs and tax withholding

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BioMarin Pharmaceutical executive George Eric Davis reported new equity awards and related tax withholding. He received a stock option for 34,690 shares of common stock at an exercise price of $57.43 per share, vesting in part on March 16, 2027 and monthly thereafter until 2036.

He also received 14,570 restricted stock units on March 16, 2026, while 7,177 shares of common stock were withheld to cover tax obligations at $58.51 per share. After these transactions, Davis directly holds 79,833 shares of common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Davis George Eric

Role EVP, Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy Common Stock)	34,690	$0.00	--
Tax Withholding	Common Stock	7,177	$58.51	$420K
Grant/Award	Common Stock	14,570	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy Common Stock) — 34,690 shares (Direct); Common Stock — 65,263 shares (Direct)

Footnotes (1)

Restricted stock units granted March 16, 2026. Price not applicable. The Reporting Person's direct holdings have been adjusted by thirteen shares to correct a previous clerical error. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

Form 4 Insider Transactions: What Each Field Means →

03/17/2026 - 08:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis George Eric

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL

94901

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/16/2026		F		7,177	D	$58.51	65,263	D
Common Stock	03/16/2026		A		14,570	A	$0⁽¹⁾	79,833⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy Common Stock)	$57.43	03/16/2026		A		34,690		03/17/2027⁽³⁾	03/15/2036	Common Stock	34,690	$0	34,690	D

Explanation of Responses:

1. Restricted stock units granted March 16, 2026. Price not applicable.

2. The Reporting Person's direct holdings have been adjusted by thirteen shares to correct a previous clerical error.

3. Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did BioMarin (BMRN) EVP George Eric Davis receive?

George Eric Davis received a stock option for 34,690 shares at an exercise price of $57.43 and 14,570 restricted stock units. These awards increase his direct economic exposure to BioMarin’s common stock as part of his executive compensation.

How do the new stock options for BioMarin (BMRN) EVP vest?

The stock option grant vests 12/48ths on March 16, 2027, then 1/48th on the 16th day of each following month. This creates a multi-year vesting schedule that ties continued service to ongoing equity ownership incentives.

Were BioMarin (BMRN) shares sold by EVP George Eric Davis in this Form 4?

The filing shows 7,177 common shares disposed of under code F at $58.51 per share. This disposition reflects shares withheld to satisfy tax obligations, not an open-market sale initiated for portfolio or valuation reasons.

How many BioMarin (BMRN) shares does George Eric Davis hold after these transactions?

Following the reported transactions, George Eric Davis directly holds 79,833 shares of BioMarin common stock. This total reflects the new restricted stock units, tax-withholding adjustments, and a small correction of 13 shares for a prior clerical error.

What is the expiration date of the new BioMarin (BMRN) stock options granted to the EVP?

The newly granted stock option for 34,690 shares expires on March 15, 2036. This long-dated expiration gives the executive a substantial window to exercise the option once vesting conditions are satisfied over time.